Tumor Lysis Syndrome Induced by Selpercatinib in Rearranged During Transfection (RET) Fusion-Positive Non-Small-Cell
Shinobu Sagawa1, Yoshitaka Tomoda2, Jun Shikama1
1Respiratory Medicine, Itabashi Chuo Medical Center, Tokyo, JPN.
This case report details tumor lysis syndrome (TLS) in a patient with non-small-cell lung cancer (NSCLC) treated with selpercatinib. It highlights the importance of early recognition and management of TLS, even without traditional risk factors.
Area of Science:
- Oncology
- Pharmacology
- Nephrology
Background:
- Tumor lysis syndrome (TLS) is a rare oncologic emergency, infrequently reported in non-small-cell lung cancer (NSCLC).
- RET fusions are an emerging target in NSCLC treatment.
- Selpercatinib is a potent targeted therapy for RET fusion-positive cancers.
More Related Videos
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
